Loading
Papillomavirus Infections / Head and Neck Neoplasms / Penile Neoplasms · Journal article
Human Vaccines & Immunotherapeutics · June 12, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective analysis of Peruvian national administrative data from 2015–2019 quantifies the burden of HPV-associated cancers in men using outpatient consultations, hospitalizations, and mortality, with HPV attribution derived from site-specific attributable fractions. The study demonstrates substantial preventable burden but does not establish causal relationships or compare interventions; it serves as a population-level descriptive epidemiological assessment to inform policy.
Retrospective observational study using national administrative and vital registration data. All men in Peru receiving outpatient care, hospitalization, or recorded at death in MINSA facilities during 2015–2019; includes all ages. Limited details on setting and coverage provided in text.. Peru, national level.
5,996 outpatient consultations for HPV-associated cancers recorded (ASR: 8.2 per 100,000), with head and neck (56.3%) and penile (30.4%) as leading sites 1,136 hospitalizations identified (ASR: 1.6 per 100,000); head and neck and penile cancers accounted for 46.3% and 45.9% respectively 2,056 outpatient consultations (ASR: 2.8) and 402 hospitalizations (ASR: 0.6) attributed to HPV after applying attributable fractions
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These data quantify a substantial HPV-attributable cancer burden in Peruvian men that has previously been understudied. Clinicians and policymakers should recognize that HPV-related cancers in men remain largely unscreened and often diagnosed late; the findings support arguments for expanded male HPV vaccination, catch-up strategies, and improved early diagnosis and treatment access.
Retrospective analysis of national administrative health data quantifying HPV-attributable cancer burden in Peruvian men; provides population-level estimates but lacks a comparator group and relies on attributable fractions applied to observational data rather than direct measurement.
As stated by the source record.
Quoted from the source exactly as published.
These data quantify a substantial HPV-attributable cancer burden in Peruvian men that has previously been understudied. Clinicians and policymakers should recognize that HPV-related cancers in men remain largely unscreened and often diagnosed late; the findings support arguments for expanded male HPV vaccination, catch-up strategies, and improved early diagnosis and treatment access.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
HPV-associated cancers in men represent a growing public health concern in Latin America, yet evidence on burden remains limited. We analyzed national data in Peru (2015-2019) to estimate outpatient consultations, hospitalization, and death rates for HPV-associated cancers and applied site-specific attributable fractions to derive HPV-attributable burden. Rates were age-standardized (ASR) to the WHO World Standard Population. Sensitivity analysis excluded mortality data for 2015-2016 to account for improvements in cause‑of‑death completeness. Between 2015 and 2019, 5,996 outpatient consultations for HPV-associated cancers in men were recorded (ASR: 8.2 per 100,000), mainly due to head and neck (56.3%) and penile (30.4%) cancers. A total of 1,136 hospitalizations were identified (ASR: 1.6 per 100,000), with head and neck and penile cancers accounting for 46.3% and 45.9% of total hospitalizations, respectively. Rates increased with age, reaching 38.0 outpatient consultations and 7.5 hospitalizations per 100,000 among men ≥60 years, but were also present among younger (<30 years) and middle-aged (30-59 years) men. Applying attributable fractions, 2,056 outpatient consultations (ASR: 2.8) and 402 hospitalizations (ASR: 0.6) were HPV-attributable, with penile cancer contributing the largest share. A total of 859 deaths from HPV-associated cancers were recorded (ASR: 1.2), of which 208 were HPV-attributable (ASR: 0.3), predominantly among men aged ≥60 years (77.2%). Sensitivity analysis had minimal impact on mortality estimates. HPV‑attributable cancers impose a substantial and preventable burden on Peruvian men. Strengthening universal HPV vaccination, ensuring high coverage, expanding multi‑age catch‑up strategies, and improving access to early diagnosis and treatment are essential to reduce future burden.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.